Allergen-Induced Dermatitis Causes Alterations in Cutaneous Retinoid-Mediated Signaling in Mice

Janine Gericke¹, Jan Ittensohn¹, Johanna Mihály¹², Sandrine Dubrac³, Ralph Rühl¹²⁴*¹

¹Laboratory of Nutritional Bioactivation and Bioanalysis, Department of Biochemistry and Molecular Biology, University of Debrecen, Debrecen, Hungary, ²Paprika Bioanalytics BT, Debrecen, Hungary, ³Epidemiology and Genomics Research Group of the Hungarian Academy of Science, Debrecen, Hungary

Abstract

Nuclear receptor-mediated signaling via RARs and PPARδ is involved in the regulation of skin homeostasis. Moreover, activation of both RAR and PPARδ was shown to alter skin inflammation. Endogenous all-trans retinoic acid (ATRA) can activate both receptors depending on specific transport proteins: Fabp5 initiates PPARδ signaling whereas Crabp2 promotes RAR signaling. Repetitive topical applications of ovalbumin (OVA) in combination with intraperitoneal injections of OVA or only intraperitoneal OVA applications were used to induce allergic dermatitis. In our mouse model, expression of IL-4, and HbeGF increased whereas expression of involucrin, Abca12 and Spink5 decreased in inflamed skin, demonstrating altered immune response and epidermal barrier homeostasis. Comprehensive gene expression analysis showed alterations of the cutaneous retinoid metabolism and retinoid-mediated signaling in allergic skin immune response. Notably, ATRA synthesis was increased as indicated by the elevated expression of retinaldehyde dehydrogenases and increased levels of ATRA. Consequently, the expression pattern of genes downstream to RAR was altered. Furthermore, the increased ratio of Fabp5 vs. Crabp2 may indicate an up-regulation of the PPARδ pathway in allergen-induced dermatitis in addition to the altered RAR signaling. Thus, our findings suggest that ATRA levels, RAR-mediated signaling and signaling involved in PPARδ pathways are mainly increased in allergen-induced dermatitis and may contribute to the development and/or maintenance of allergic skin diseases.

Introduction

Atopic dermatitis (AD) is the most common inflammatory skin condition, predominantly affecting infants and children and characterized by pruritus, eczematous lesions, and skin dryness. Furthermore, the disease is commonly associated with allergic conditions such as allergic rhinitis and asthma. AD affects 10–30% of children and 2–10% of adults in industrialized countries, with a marked increase in AD prevalence during the past 30 years [1–3]. While various studies reported an “outside-inside-outside” pathogenic mechanism of AD [4–6], its exact pathogenesis is not yet fully elucidated.

Vitamin A and its derivatives, the retinoids, are essential for skin physiology [7] through their role in the regulation of several aspects of skin cell proliferation, differentiation, apoptosis, immune regulation and epidermal barrier function [8,9]. Noticeably, alterations of retinoid metabolism and signaling were found in skin of patients with various skin diseases, such as psoriasis [10], ichthyosis [11], and recently by our group in AD [12]. Thereby, it is unclear whether these alterations are the trigger or if they are consequence of these skin diseases. Furthermore, it was previously shown that retinoids are able to modify the immune phenotype of atopic diseases such as AD [13,14].

Retinoids mediate their function mainly via signaling through nuclear hormone receptors, i.e. retinoic acid receptor (RAR) α, β, and γ and retinoid X receptor (RXR) α, β, and γ. RARs and other nuclear receptors, like peroxisome proliferator-activated receptors (PPAR) α, δ, β, and γ, function as ligand-dependent transcription factors and regulate the expression of various genes after heterodimerization with RXR [15]. Within these three receptor families, RARγ, RXRα and PPARδ are the most abundant subtypes present in skin [16,17].

PPAR-mediated pathways are important in skin physiology because they are involved in epidermal barrier recovery, keratinocyte differentiation and lipid synthesis [16]. For example, overexpression of PPARδ in the epidermis causes a psoriasis-like skin disease featuring hyperproliferation of keratinocytes, dendritic cell accumulation, and endothelial activation [18]. Interestingly, a cross-talk exists between RAR and PPARδ pathways. Indeed, RARγ and PPARδ can both be activated by the endogenous RAR ligand all-trans retinoic acid (ATRA), depending on specific transport proteins. The cellular retinoic acid binding protein 2

Citation: Gericke J, Ittensohn J, Mihály J, Dubrac S, Rühl R (2013) Allergen-Induced Dermatitis Causes Alterations in Cutaneous Retinoid-Mediated Signaling in Mice. PLoS ONE 8(8): e71244. doi:10.1371/journal.pone.0071244

Editor: Michael Schubert, Laboratoire de Biologie du Développement de Villefranche-sur-Mer, France

Received February 27, 2013; Accepted June 27, 2013; Published August 15, 2013

Copyright: © 2013 Gericke et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The project is implemented through the New Hungary Development Plan, co-financed by the European Social Fund. RR and SD are members of the COST action BM0903 “SkinBAD-skin barrier and atopic diseases”. RR is also a member of the COST action BM1007 “Mast Cells and Basophils – Targets for Innovative Therapies”. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: Since Dr. Ralph Rühl has multiple affiliations, the authors would like to declare that he is also the owner and chief executive officer of the company Paprika Bioanalytics BT. However this does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials. Moreover, the submitted manuscript is neither related to any patents, patent applications, or products in development or for market, nor does any other competing interest (e.g. employment, consultancy, etc.) exist. All authors state no conflict of interest.

* E-mail: ralphruehl@web.de
fields per section). For detailed information on used antibodies and microscope using 40x objective lenses and a calibrated grid (six fields per section). For detailed information on used antibodies and staining procedure refer to Materials and Methods S1a.

The aim of the present study was to determine whether the induction of allergic immune responses in the skin by combined systemic and topical treatments with ovalbumin (OVA) is able to modify retinoid metabolism and retinoid-mediated signaling in the skin of mice. Furthermore, we studied the effects of systemic OVA sensitization without further topical sensitization on skin retinoid metabolism as a potential model for an inside-outside pathomechanism of allergic skin disorders. Our final aim was to determine via which nuclear hormone receptor-mediated pathways retinoid signaling might be regulated to modify skin inflammation and homeostasis in allergen-induced dermatitis.

Materials and Methods

Sensitization of Mice

8–10 weeks old female BALB/c mice, were obtained from and housed within the animal facility of the University of Debrecen, Hungary. Animals were maintained in single cages with standard animal chow and water ad libitum. All experimental procedures were approved by the Committee of Animal Research of the University of Debrecen, Hungary (Approval number: 25/2006 DEMAB).

Sensitization of mice was performed by repetitive systemic application of OVA and allergen-induced dermatitis based on a model previously reported [24,25]. Briefly, mice were sensitized at days 47, 60 and 67 with 10 μg OVA intraperitoneally (i.p.) (Sigma-Aldrich, Budapest, Hungary) adsorbed to 1.5 mg aluminum hydroxide (Al(OH)₃) (Thermoscientific, Budapest, H) or with phosphate-buffered saline (PBS; control) (Figure 1a). For combined treatment [24], mice were sensitized i.p. on days 1, 14 and 21 with 10 μg OVA adsorbed to 1.5 μg Al(OH)₃. This was followed by topical application of 100 μg OVA adsorbed to 1.5 mg Al(OH)₃ in 100 μl PBS (weekly dose) onto shaved back skin, divided into four applications of 25 μl every other day of one week (Figure 1b). Epicutaneous (e.c.) treatment was repeated for a total exposure of three weeks separated by two-week intervals. Three days after the last treatment (day 70) mice were euthanized: skin and serum samples were collected and kept at −80°C until analysis. Plasma IgE concentration was measured using the mouse ELISA kit from BD-Pharmingen.

Histological Analysis

Skin biopsies of were taken from similar body sites, fixed overnight with 4% paraformaldehyde at 4°C, and embedded in paraffin. Five-micrometer sections were stained with hematoxylin and eosin (H&E) or Giemsa. Mast cells were quantified under a light microscope using 20x lenses and a calibrated grid (six fields per sample) while epidermal thickness was measured using 10x lenses (five measurements per mouse).

Immunohistochemical Analysis

To quantitate lymphocytes and dendritic cells in the skin, CD3⁺, CD4⁺, CD8⁺, MHC-class II⁺ and CD11c⁺ cells in frozen skin sections were counted under an Olympus BX60 epifluorescence microscope using 40x objective lenses and a calibrated grid (six fields per section). For detailed information on used antibodies and staining procedure refer to Materials and Methods S1a.

Central to this study was that Crapb2 initiates RAR signaling, whereas the fatty acid-binding protein 5 (Fabp5) promotes PPARβ-mediated signaling after ATRA-binding [19,20]. However, these findings are controversially discussed in the literature [21–23]. Moreover, PPARβ activation has been reported at high ATRA concentrations suggesting that tissue levels of ATRA can determine which nuclear receptor pathways are up-regulated and thereby influence the gene expression profile [19,20].

The determination of retinoid signaling might be regulated to modify skin inflammation and homeostasis in allergen-induced dermatitis.

Student’s t-test. Differences were considered significant at p<0.05.
Results

Systemic Sensitization with OVA Induces Mild Allergen-induced Dermatitis When Compared to Additional Topical OVA Applications

BALB/c mice were systemically sensitized with OVA in addition or not to topical sensitization onto shaved back skin (Figure 1a and b) and compared with PBS-injected mice (controls). Sensitization with OVA induced mild but statistically significant focal hyperplasia with a two-fold (OVA i.p.; \( p < 0.001 \) vs. PBS i.p.) or three-fold (OVA i.p.+e.c.; \( p < 0.001 \) vs. PBS i.p.; \( p < 0.001 \) vs. OVA i.p.) increase in epidermal thickness, respectively (Figure 1c). Histological analysis further revealed scaly skin in both OVA-sensitized groups (Figure 1c). Interestingly, repeated systemic sensitization with OVA did not alter total serum IgE levels compared to control mice (Figure 1d). However, combined systemic and topical sensitization leading to allergen-induced dermatitis resulted in significantly increased total serum IgE (21.696 ± 1.655 ng/ml) when compared to controls and systemically sensitized mice (data not shown). Altogether, numbers of mast cells, macrophages and dermal dendritic cells were significantly higher only in allergen-induced dermatitis (Table 1). Thus, repeated systemic sensitization with OVA is sufficient to initiate an inflammatory immune response in the skin whereas additional topical sensitization is required to induce full allergen-mediated dermatitis in mice [24,25].

Expression of Th1- and Th2-type Immune Response Genes is only Altered in Allergen-induced Dermatitis

Expression of genes relevant for Th1- or Th2-type immune response was analyzed in the skin of mice by qRT-PCR and TLDA. As shown in Table 2, gene expression levels of the inflammation-associated keratin 17 (Krt17) was moderately increased in the skin of OVA-sensitized mice. In contrast, expression of Th1 related genes including interferon \( \gamma \) (Ifng) and interleukin 12A (Il12a) and of Th2 associated genes including interleukin 4 (Il4), interleukin 10 (Il10), chemokine ligand 11 (eotaxin 1; Ccl11) and its corresponding chemokine receptor 3 (Ccr3) was significantly elevated only in the skin of mice with allergen-induced dermatitis (Table 2). Altogether, these results (Tables 1 and 2) show that only combined systemic and topical....
Three-dimensional expression levels of 3-Hydroxy-3-methylglutaryl-CoA synthase 2 genes related to the epidermal lipid compartment were mainly up-regulated in the skin of mice with allergen-induced dermatitis and/or solely systemic OVA sensitization (Table 2). Noticeably, only expression of ATP-binding cassette A12 (Abca12), which is responsible for lipid loading into lamellar bodies, was decreased in OVA-treated groups (Table 2). Taken together, our results suggest that systemic sensitization with OVA is sufficient to decrease expression of differentiation markers and to increase expression of proteins involved in the cutaneous lipid metabolism. This, in turn, might lead to an impaired epidermal barrier function.

Systemic Sensitization with OVA Triggers IL-4 Serum Levels

Levels of the cytokines IL-4, TSLP and IL-12 (IL-12p70) were determined in the sera of OVA-sensitized and control mice. IL-4 but not TSLP was significantly increased in both OVA-treated groups (Table 1, Figure 2a). Serum levels of IL-12, a Th1-type cytokine, remained similar in all groups (Table 1).

Retinoic Acid Levels and Retinoid Metabolism are Increased in Allergen-induced Dermatitis

While retinoid-mediated signaling in skin is involved in several physiological processes, little is known about RAR-mediated signaling in inflammatory skin diseases [12]. By means of our mouse model we aimed to investigate whether repeated systemic and combined systemic and topical sensitizations with OVA are able to induce changes in retinoid metabolism and retinoid-mediated signaling on the gene expression level in skin. After sensitization, expression of short chain dehydrogenase/reductase 16C5 (Sdr16c5), responsible for the oxidation of retinol to retinal, was induced compared to controls while expression of retinol dehydrogenase 10 (Rdh10) remained unchanged (Table 3). In contrast, expression of enzymes responsible for the conversion of retinol to the bioactive vitamin A derivative ATRA (aldehyde dehydrogenases; Aldh1a1, 1a2, and 1a3) was significantly increased in allergen-induced dermatitis (Table 3). Importantly, we found significantly elevated concentrations of ATRA only in the skin of mice with allergen-induced dermatitis (Figure 2b, Table S1), while retinol levels remained unchanged (Table S1). Different retinoid receptors mediate the effects of ATRA in skin. Parallel to ATRA skin content, elevated mRNA levels of RARγ and RXRα, both the most abundant retinoid receptors in skin, were evidenced only in allergen-induced dermatitis (Table 3). To further investigate the induction of retinoid-mediated signaling in sensitized skin, we next assessed expression of RAR target genes. Accordingly, we found that expression of genes encoding RA degradation enzymes, cytochrome P450 26a1 (Cyp26a1; eight-fold induction) and Cyp26b1 (two-fold increase) was increased in allergen-induced dermatitis (Table 3). Expression of proteins involved in retinoid transport (Rbp1, Crabp2) and metabolism (Lrat) was similarly increased in the skin of mice treated with OVA, regardless of further topical sensitization with OVA, whereas expression of RAR target genes not involved in retinoid signaling (Krt14, Rarres2, Tgm2) was not significantly altered (Table 3). Notably, the ratio of Fabp5 vs. Crabp2 gene expression, both delivering ATRA to their respective cognate receptors, significantly increased in allergen-induced dermatitis (Figure 2c). Thus, allergen-induced dermatitis might lead to increased ATRA levels in the skin and dysregulated sensitizations with OVA fully recapitulate allergen-induced dermatitis symptoms, which are also found in chronic AD [27–31].

### Systemic Sensitization with OVA Induced Mild Allergic Dermatitis when Compared to Additional Topical OVA Applications

| Analysis | PBS i.p. | OVA i.p. | OVA i.p.e.c. |
|----------|---------|---------|-------------|
| Inflammatory cell infiltrate in skin | | | |
| Mast cells | 7 ± 1 | 27 ± 2*** | 45.3 ± 3*** |
| Eosinophils | 0 ± 0 | 5 ± 1* | 9 ± 2*** |
| Macrophages (MHC II+CD11c) | 307 ± 16 | 369 ± 21 | 474 ± 14*** |
| Dermal dendritic cells (MHC II+CD11c) | 40 ± 3 | 59 ± 4 | 90 ± 10*** |
| CD3+ lymphocytes | 164 ± 13 | 240 ± 15** | 285 ± 10*** |
| CD4+ lymphocytes | 4 ± 1 | 11 ± 2 | 14 ± 2** |
| Cytokine serum levels (pg/mL) | | | |
| Th1-type | | | |
| Interleukin 12 (IL-12) | 7.4 ± 3.9 | 6.5 ± 4.4 | 8.4 ± 5.6 |
| Th2-type | | | |
| Interleukin 4 (IL-4) | 73 ± 22 | 179 ± 24* | 198 ± 15** |
| Thymic stromal lymphopoietin (Tslp) | 3.5 ± 0.5 | 3.7 ± 1.2 | 3.4 ± 0.4 |

* Data are indicated as mean ± SEM. Statistical significance (p) was tested using one-way ANOVA followed by Tukey’s multiple comparison test. p<0.05, ***p<0.001, and ****p<0.0001, versus PBS i.p.; p<0.05, **p<0.01, and ***p<0.001, versus OVA i.p.; 2Positively stained cells were counted in six fields per section of n = 5 (IHC-staining) or n = 8 animals (Giemsa-staining), respectively, and expressed as cells per mm².
3Determined in IHC-stained skin sections.
4Determined in Giemsa-stained skin sections.
5Cytokine levels in sera were determined as triplicate measurements of n = 4 mice per group using Quantikine mouse immunoassay kits. Data are indicated as pg/mL.

DOI:10.1371/journal.pone.0071244.t001
retinoid metabolism and signaling at least in our mouse model of the disease.

**Gene Targets Involved in and Mediated by PPARδ Pathways in Skin are Mainly Up-regulated in Allergen-induced Dermatitis**

Gene expression of PPARδ as well as several of its target genes in skin is presented in Table 2. Systemic or systemic plus topical sensitization of mice with OVA led to reduced PPARδ gene expression compared to controls and this decrease was somewhat more pronounced in mice systemically sensitized only. In contrast, mRNA expression of Fabp5, the fatty acid binding protein which delivers ligands to PPARδ, was increased after sensitization with OVA (Table 2). Moreover, keratin 6b (Krt6b), keratin 16 (Krt16), heparin-binding EGF-like growth factor (Hbegf) and Hmgcs2, all of which known to be induced upon PPARδ activation and involved in epidermal barrier homeostasis [18,32,33], showed significantly elevated gene expression levels in skin after systemic and topical sensitization. Only the PPARδ target gene Abca12[34], which is responsible for epidermal barrier formation and maintenance, showed decreased mRNA levels in both OVA treatment groups (Table 2). Altogether, our results suggest an induction of gene targets which are involved in PPARδ signaling.

| Table 2. Systemic and topical OVA sensitization results in inflammation, disturbs epidermal barrier homeostasis, and induces PPARδ target gene expression in skin. |
| --- |
| **Gene name** | **Symbol** | **OVA i.p.** | **OVA i.p.+e.c.** |
| **Immune response** |  |  |  |
| Keratin 17 | Krt17 | 1.6±0.2* | 1.7±0.2** |
| Th1-type | Interleukin 12A | Il12a | 1639±719 | 2613±740* |
| Interferon γ | Ifng | 11.1±5.4 | 22.1±2.8** |
| Th2-type | Interleukin 4 | Il4 | 11.7±4.5 | 92.7±30.9** |
| Interleukin 10 | Il10 | 12.4±5.5 | 32.7±13.1* |
| Chemokine (CC motif) ligand 11/eotaxin 1 | Ccl11 | 0.2±0.2 | 13.8±5.1* |
| Chemokine (CC motif) receptor 3 | Ccr3 | 63.7±34.4 | 1763±534** |
| **Epidermal barrier homeostasis** |  |  |  |
| ATP-binding cassette A12 | Abca12 | 0.3±0*** | 0.6±0.1** |
| Invovlucrin | Iv1 | 0.6±0.1* | 0.4±0.0** |
| Loricrin | Lor | 0.5±0* | 0.8±0.1** |
| Serine peptidase inhibitor, Kazal-type 5 | Spink5 | 0.2±0*** | 0.4±0*** |
| Matrix metalloproteinase 9 | Mmp9 | 0.1±0** | 0.6±0.1** |
| S100 calcium binding protein A7A/psoriasin | S100a7a | 2.6±0.3** | 2.1±0.3* |
| 3-Hydroxy-3-methylglutaryl-CoA synthase 2 | Hmgcs2 | 0.4±0.1 | 4.4±1.1* |
| Serine palmitoyltransferase long chain base subunit 2 | Sptlc2 | 12.2±0.3 | 33.8±10.6*** |
| UDP-glucose ceramide glucosyltransferase | Ugcg | 196±16.9*** | 161±14.4*** |
| Alkaline ceramidase 1 | Acer1 | 2.2±0.6 | 3.9±0.3*** |
| **PPARδ signaling** |  |  |  |
| Peroxisome proliferator-activated receptor δ | Ppard | 0.4±0** | 0.6±0.0* |
| Fatty acid-binding protein 5 | Fabp5 | 1.7±0.3 | 2.2±0.2** |
| ATP-binding cassette A12 | Abca12 | 0.3±0*** | 0.6±0.1*** |
| Keratin 6B | Krt6b | 5.8±0.6 | 632±177*** |
| Keratin 16 | Krt16 | 0.5±0 | 5.7±1.2*** |
| Heparin-binding EGF-like growth factor | Hbegf | 11.1±0.1 | 2.1±0.3** |
| 3-Hydroxy-3-methylglutaryl-CoA synthase 2 | Hmgcs2 | 0.4±0.1 | 4.4±1.1* |

e.c., epicutaneous; i.p., intraperitoneal; OVA, ovalbumin; Th, T-helper cell.
Enumerated twice because the gene is relevant for two pathways.
Fold change data are expressed as mean ± SEM (n = 6) and were determined in skin specimen of sensitized mice by TLDA or qRT-PCR. Statistical significance (p) was tested using one-way ANOVA followed by Tukey’s multiple comparison test.

* p<0.05,
** p<0.01, versus control (PBS i.p.);
*** p<0.001, versus control (PBS i.p.);
# p<0.05, and ### p<0.001, versus OVA i.p.
doi:10.1371/journal.pone.0071244.t002
pathways, most noticeably Fabp5, in murine skin in response to systemic and topical OVA sensitization.

**Systemic Sensitization with OVA Increases Fabp5 Protein Levels**

Because Fabp5 gene expression in skin was induced after repeated systemic OVA sensitization (Table 2), we next assessed levels of Fabp5 protein in the skin of mice in our various experimental conditions. Levels of Fabp5 protein as measured by Western Blots, increased in skin of mice systemically sensitized with OVA compared to controls (Figure 3a). However, highest Fabp5 protein levels were detected in whole skin of mice systemically treated with OVA (Figure 3a). In order to determine the localization of Fabp5 across the skin, we performed immunohistochemical analysis. We found intense staining for Fabp5 in the thickened epidermis and around hair follicles of mice treated with OVA (Figure 3b). Thus, systemic sensitization with OVA is sufficient to increase levels of Fabp5 in the skin of mice.

**Discussion**

The present study demonstrates that the immune response in allergen-induced dermatitis is associated with increased retinoid signaling and RA concentrations in the skin. Moreover, signaling via PPARδ-mediated pathways, mostly through Fabp5 upregulation, was mainly enhanced in allergen-induced dermatitis. Thus, retinoid-mediated signaling is involved in the pathogenesis and/or maintenance of allergic dermatitis or further atopic skin diseases such as AD, but the exact pathway is not yet determined.
High RA levels in the skin, as observed in the present work, might directly impact on systemic and local immune responses [14,35–38]. In our mouse model of allergen-induced dermatitis, we found a mixed Th1- and Th2-type immune response in the skin and high numbers of infiltrating dermal macrophages, dendritic cells and mast cells (Table 1 and 2). In contrast, mice systemically treated with OVA exhibited only a partial phenotype with lower inflammatory infiltrates and cytokine expression in the skin. Interestingly, the highest levels of immune response-related gene expression, inflammatory cell infiltrates and serum cytokines correlated with increased expression of RA synthesizing enzymes and ATRA levels in inflamed skin. Thus, these data suggest that only overt allergen-induced dermatitis leads to an increased ATRA concentration and altered RA signaling in the skin.

Table 3. Systemic and topical OVA sensitizations induce retinoic acid synthesis and dysregulate retinoid-mediated signaling in skin of mice.

| Gene name                                      | Symbol | OVA i.p. | OVA i.p.+e.c. |
|------------------------------------------------|--------|----------|---------------|
| **Retinal synthesis**                          |        |          |               |
| Short chain dehydrogenase/reductase 16C5       | Sdr16c5| 1.7 ± 0.2*| 1.8 ± 0.2*    |
| Retinol dehydrogenase 10                       | Rdh10  | 1.1 ± 0.1 | 1.3 ± 0.1     |
| **Retinoic acid synthesis**                    |        |          |               |
| Aldehyde dehydrogenase 1A1                     | Aldh1a1| 1.8 ± 0.2 | 2.4 ± 0.4**   |
| Aldehyde dehydrogenase 1A2                     | Aldh1a2| 0.5 ± 0   | 3.9 ± 1.3**   |
| Aldehyde dehydrogenase 1A3                     | Aldh1a3| 4.8 ± 0.4**| 4.0 ± 0.8**   |
| **Retinoid receptors**                         |        |          |               |
| Retinoic acid receptor α                        | Rara   | 0.8 ± 0.1 | 1.0 ± 0.1     |
| Retinoic acid receptor β                        | Rarb   | 0.8 ± 0.1 | 0.9 ± 0.1     |
| Retinoic acid receptor γ                        | Rarg   | 0.8 ± 0.1 | 1.3 ± 0.2**   |
| Retinoid X receptor α                           | Rxra   | 0.7 ± 0.1 | 1.6 ± 0.2***  |
| **RAR target genes involved in retinoid signaling** |        |          |               |
| Retinoic acid degradation                       |        |          |               |
| Cytochrome P450 26A1                            | Cyp26a1| 2.1 ± 0.7 | 7.9 ± 2.2**   |
| Cytochrome P450 26B1                            | Cyp26b1| 0.6 ± 0.1 | 1.9 ± 0.2**   |
| **Retinoid transport proteins**                 |        |          |               |
| Cellular retinoic acid binding protein 1        | Rbp1   | 3.5 ± 0.2***| 3.0 ± 0.2***  |
| Cellular retinoic acid binding protein 2        | Crabp2 | 1.3 ± 0.1 | 1.4 ± 0.1     |
| **Retinol esterification**                     |        |          |               |
| Lecithin-retinol acyltransferase                | Lrat   | 2.4 ± 0.3 | 2.5 ± 0.7     |
| Keratin 4                                       | Krt4   | 0.6 ± 0.2 | 0.3 ± 0*      |
| Retinoic acid receptor responder 2              | Rares2 | 0.5 ± 0.1*| 0.6 ± 0.1     |
| Transglutaminase 2                              | Tgm2   | 0.9 ± 0.1 | 0.7 ± 0.1     |

Fold change data are expressed as mean ± SEM (n = 6) and were determined in skin specimen of sensitized mice by TLDA. Statistical significance (p) was tested using one-way ANOVA followed by Tukey’s multiple comparison test. *p<0.05, **p<0.01, ***p<0.001, versus control (PBS i.p.); #p<0.05, ##p<0.01, and ###p<0.001, versus OVA i.p.

doi:10.1371/journal.pone.0071244.t003

One of the major outcomes of the present work was to demonstrate that systemic sensitization of mice per se is sufficient to induce partial skin immune responses and an impairment of expression of key genes involved in skin homeostasis and barrier function (Table 1 and 2, Figure 2a). Previous studies and reviews reported an “outside-inside-outside” pathogenic mechanism of AD [4–6]. In contrast, our data support an “inside-out”
mechanism significantly contributing to the development of overt skin inflammation.

It has previously been shown that ATRA is not only ligand of RARs but can also activate PPARδ and induce PPARδ target gene expression. PPARδ signaling is favored instead of RAR pathways when the ratio of the lipid transporters Fabp5 vs. Crabp2 is high within cells such as keratinocytes [19,20]. We determined highest Fabp5 protein levels in the skin of mice treated systemically with OVA (Figure 3a). In contrast, immunohistochemical analysis showed particularly intense staining in the epidermis and around hair follicles of mice with allergen-induced dermatitis (Figure 3b). In the literature, Fabp5 protein is described to be predominantly present in epidermis [41], sebaceous glands and hair follicles [42] and in subcutaneous adipocytes [43]. However, in our study western blot analysis was performed from whole skin, therefore, a larger increase of Fabp5 protein expression in dermis and/or subcutaneous fat after systemic OVA treatment compared to systemic and topical treatment may explain the apparent discrepancy between Figures 3a and 3b. Notably, in our mouse model, the Fabp5 vs. Crabp2 ratio was increased in allergen-induced dermatitis (Figure 2c). This data might suggest favored ATRA signaling through PPARδ which may significantly contribute to the specific gene expression patterns observed in this study (see below and indicated in Figure 3c). PPARδ signaling and several of its target genes were previously found increased in psoriasis and lesional AD skin [18,33,44] and Romanowska et al. [18] further demonstrated the induction of an inflammatory skin disease similar to human psoriasis in PPARδ-overexpressing mice. Interestingly, in our mouse model of allergen-induced dermatitis we observed an increased expression of several of the investigated target genes involved in PPARδ signaling pathways in skin. Though further investigations potentially involving PPARδ knockout mice would be required to confirm these data, our results suggest favored ATRA-mediated PPARδ signaling in allergen-induced dermatitis.

Most notably, several RAR target genes involved in retinoid signaling were induced in allergen-induced dermatitis, whereas expression of RAR targets which are not implicated in retinoid signaling (Krt4, Rarres2, Tgm2) was not significantly altered. Thus, expression of genes involved in RA synthesis as well as degradation, transport and esterification, and especially of RAR target genes was increased in allergen-induced dermatitis. In contrast, expression of RAR target genes rather related to epidermal differentiation remained unaltered or reduced. These data thus indicate that potentially increased ATRA synthesis via Aldh1a enzymes and elevated ATRA levels in mouse skin observed in allergen-induced dermatitis might not result in an overall increase of RAR-mediated signaling. Furthermore, OVA treatment might also affect the level of several other lipids and nuclear receptor agonists than ATRA in mouse skin.

In summary, allergen-induced dermatitis is associated with increased retinoid signaling and elevated ATRA levels in the skin. Because expression of genes involved in all aspects of RA metabolism is increased, whereas expression of RAR target genes involved in other pathways such as epidermal differentiation remains largely unchanged, allergen-induced dermatitis might additionally redirect intracellular retinoid flux and metabolism. Moreover, PPARδ gene targets were mainly induced indicating
that RAR-mediated signaling and certain pathways/molecules involved in PPARs signaling are altered in allergic dermatitis skin. Furthermore, systemic sensitization with an allergen is sufficient to modify the expression of genes central to epidermal homeostasis suggesting an “inside-out” effect of allergen in allergic skin disease pathogenesis possibly by increasing allergen penetration through the skin. Whether disturbed retinoid metabolism and retinoid-mediated signaling are symptoms or potential initiators of atopic sensitization still remains to be elucidated.

Supporting Information

Table S1 Systemic and topical OVA sensitizations result in increased all-trans retinoic acid levels in skin.

**Materials and Methods S1 Immunohistochemical analysis.**

**Materials and Methods S2 Determination of FABP5 protein in skin.**

**Materials and Methods S3 Protocol for the determination of all-trans retinoic acid levels in skin by HPLC MS-MS method.**

**Acknowledgments**

The authors thank Eva Papp for her excellent technical assistance.

**Author Contributions**

Conceived and designed the experiments: JG RR. Performed the experiments: JG JJ JM. Analyzed the data: JG. Contributed reagents/materials/analysis tools: SD RR. Wrote the paper: JG. Revised the manuscript: RR SD.

**References**

1. Bieber T (2008) Atopic dermatitis. N Engl J Med 358: 1483–1494.
2. Bieber T, Novak N (2009) Pathogenesis of atopic dermatitis: new developments. Curr Allergy Asthma Rep 9: 291–294.
3. Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, et al. (2006) Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 38: 441–446.
4. Cork MJ, Danybe SC, Vaudoupoulos Y, Hadgraft J, Lane ME, et al. (2009) Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol 129: 1892–1908.
5. Elias PM, Hatanu Y, Williams ML (2008) Basis for the barrier abnormality in atopic dermatitic: outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol 121: 1337–1343.
6. Marsella R, Samuelson D (2009) Unravelling the skin barrier: a new paradigm for atopic dermatitis and house dust mites. Vet Dermatol 20: 533–540.
7. Roos TC, Jungert FK, Merk HF, Bickers DR (1996) Retinoid metabolism in the skin. Pharmacol Rev 50: 315–333.
8. Elias PM, Fritsch PO, Lampe M, Williams ML, Brown BE, et al. (1981) Retinoid acid. Mol Pharmacol 74: 1269–1277.
9. Elias PM (1987) Retinoid effects on the epidermis. Dermatologica 175 Suppl 1: 28–36.
10. Saurat JH (1999) Retinoids and psoriasis: novel issues in retinoid pharmacology and implications for psoriasis treatment. J Am Acad Dermatol 41: 82–9.
11. Mevorah B, Salomon D, Siegenthaler G, Holli D, Meier ML, et al. (1996) Ichthyosiform dermatosis with superficial blister formation and peeling: evidence for a desmosomal anomaly and altered epidermal vitamin A metabolism. J Am Acad Dermatol 34: 379–385.
12. Mihaly J, Gamliel A, Worm M, Ruhl R (2011) Decreased retinoid concentration and retinoid signalling pathways in human atopic dermatitis. J Bioenerg Biomembr 43: 226–330.
13. Ruhl R, Garcia A, Schweigert FJ, Worm M (2004) Modulation of cytokine production by low and high retinoids in ovabumin-sensitized mice. Int J Vitam Nutr Res 74: 279–284.
14. Ruhl R, Hanel A, Garcia AL, Dahlen A, Herz U, et al. (2007) Role of vitamin A elimination or supplementation diets during postnatal development on the allergic sensitisation in mice. Mol Nutr Food Res 51: 1173–1181.
15. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, et al. (1995) The nuclear receptor superfamily: the second decade. Cell 83: 835–839.
16. Michalik L, Wahli W (2007) Peroxisome proliferator-activated receptors (PPARs) in skin health, repair and disease. Biochim Biophys Acta 1771: 991–1001.
17. Fisher GJ, Talwar HS, Xiao JH, Datta SC, Reddy AP, et al. (1994) Immunological identification and functional quantitation of retinoic acid and retinoid X receptor proteins in human skin. J Biol Chem 269: 20629–20635.
18. Romanowska M, Reilly L, Palmer CN, Gustafsson MJ, Forster J (2010) Activation of PPARbeta/delta causes a psoriasis-like skin disease in vivo. PLoS One 5: e10701.
19. Shaw N, Elholm M, Noy N (2005) Retinoic acid is a high affinity selective ligand for the peroxisome proliferator-activated receptor beta/delta. J Biol Chem 280: 41539–41542.
20. Schug TT, Berry DC, Shaw NS, Travis SN, Noy N (2007) Opposing effects of retinoid on cell growth result from alternate activation of two different nuclear receptors. Cell 129: 723–733.
21. Breyer M, Meier N, Ries S, Muller-Brusselbach S, Muller R (2008) Ligand-mediated regulation of peroxisome proliferator-activated receptor (PPAR) beta/delta: a comparative analysis of PPAR-selective agonists and all-trans retinoic acid. Mol Pharmacol 74: 1269–1279.
22. Berry DC, Noy N (2009) All-trans-retinoic acid represses obesity and insulin resistance by activating both peroxisome proliferator-activated receptor beta/ delta and retinoic acid receptor. Mol Cell Biol 29: 3296–3299.
23. Borland MG, Khoozie C, Albrecht PP, Zhu B, Lee C, et al. (2011) Stable over-expression of PPARbeta/delta and PPARgamma to examine receptor signaling in human HaCaT keratinocytes. Cell Signal 23: 2039–2050.
24. Dahnet A, Koch C, Ernst D, Schneller C, Hartmann S, et al. (2008) Systemic PPARgamma ligation inhibits allergic immune response in the skin. J Invest Dermatol 128: 2211–2218.
25. Weise C, Zhu Y, Ernst D, Kohl AA, Worm M (2011) Oral administration of Escherrichia coli Nissle 1917 prevents allergen-induced dermatis in mice. Exp Dermatol 20: 805–809.
26. Ruhl R (2006) Method to determine 4-oxo-retinoic acids, retinoic acids and retinol in serum and cell extracts by liquid chromatography/diode-array detection atmospheric pressure chemical ionisation tandem mass spectrometry. Rapid Commun Mass Spectrom 20: 2497–2504.
27. Grewe M, Bruijnzeel-Koomen CA, Schopf E, Thepen T, Langeveld-Wildschut AG, et al. (1998) A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis. Immunity Today 19: 359–361.
28. Horikawa T, Nakayama T, Hikita I, Yamada H, Fujisawa R, et al. (2002) IFN-gamma-inducible expression of thymus and activation-regulated chemokine/ CCL17 and macrophage-derived chemokine/CCL22 in epidermal keratinocytes and their roles in atopic dermatism. Int Immunol 14: 767–773.
29. Leung DY (1995) Atopic dermatism: the skin as a window into the pathogenesis of chronic allergic diseases. J Allergy Clin Immunol 96: 302–318; quiz 319.
30. Leung DY, Bieber T (2005) Atopic dermatism. Lancet 361: 151–160.
31. Wierfel T, Morita A, Grewe M, Reinu H, Wahn U, et al. (1996) Allergen specificity of skin-infiltrating T cells is not restricted to a type-2 cytokine pattern in chronic skin lesions of atopic dermatism. J Invest Dermatol 107: 871–876.
32. Calleja C, Messaddeq N, Chapellier B, Yang H, Krezel W, et al. (2006) Genetic and pharmacological evidence that a retinoic acid cannot be the RXR-activating ligand in mouse epidermis keratinocytes. Genes Dev 20: 1325–1338.
33. Romanowska M, al Yacoub N, Seidell H, Donandt S, Gerken H, et al. (2008) PPARdelta enhances keratocyte proliferation in psoriasis and induces heparin-binding EGF-like growth factor. J Invest Dermatol 128: 110–124.
34. Jiang YJ, Uchida Y, Lau B, Kim P, Miao C, et al. (2009) Ceramide stimulates ABCA12 expression via peroxisome proliferator-activated receptor [delta] in human keratinocytes. J Biol Chem 284: 18942–18952.
35. Ruhl R (2007) Effects of dietary retinoids and carotenoids on immune development. Proc Nutr Soc 66: 430–439.
36. Schuster GU, Kenyon NJ, Stephens CB (2008) Vitamin A deficiency decreases and high dietary vitamin A increases disease severity in the mouse model of asthma. J Immunol 180: 1084–1092.
37. Stephens CB (2001) Vitamin A, infection, and immune function. Annu Rev Nutr 21: 167–192.
38. Stephens CB, Borowsky AD, Lloyd KC (2007) Disturbance of Rarxa gene in thymocytes and T lymphocytes modestly alters lymphocyte frequencies, proliferation, survival and T helper type 1/type 2 balance. Immunology 121: 401–404.
39. Ito Y, Satoh T, Takayama K, Miyagishi C, Walls AF, et al. (2011) Basophil gamma-inducible expression of thymus and activation-regulated chemokine/ CCL17 and macrophage-derived chemokine/CCL22 in epidermal keratinocytes and their roles in atopic dermatism. Int Immunol 14: 767–773.
41. Ogawa E, Owada Y, Ikawa S, Adachi Y, Egawa T, et al. (2011) Epidermal FABP (FABP5) regulates keratinocyte differentiation by 13(S)-HODE-mediated activation of the NF-κB signaling pathway. J Invest Dermatol 131: 604–612.

42. Collins CA, Watt FM (2008) Dynamic regulation of retinoic acid-binding proteins in developing, adult and neoplastic skin reveals roles for beta-catenin and Notch signalling. Dev Biol 324: 55–67.

43. Zhou G, Wang S, Wang Z, Zhu X, Shu G, et al. (2010) Global comparison of gene expression profiles between intramuscular and subcutaneous adipocytes of neonatal landrace pig using microarray. Meat Sci 86: 440–450.

44. Westergaard M, Hemmingsen J, Johansen C, Rasmussen S, Svendsen ML, et al. (2003) Expression and localization of peroxisome proliferator-activated receptors and nuclear factor kappaB in normal and lesional psoriatic skin. J Invest Dermatol 121: 1104–1117.